Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Pregnyl Market Expected To Reach $ Billion By 2030 At % CAGR
The expansion observed during the historical period resulted from the rising incorporation of hCG into fertility treatments, the proliferation of IVF and ART centers, its well-established application for managing male hypogonadism, heightened medical proficiency in hormonal interventions, and the accessibility of injectable fertility medications.
The expansion observed during the forecast period is driven by a higher prevalence of infertility, greater demand for assisted reproduction, broader availability of fertility treatment options, heightened awareness regarding male infertility, and the growing adoption of personalized hormone regimens. Key developments shaping this period include a surge in demand for fertility hormone therapies, their increased application in assisted reproductive techniques, a stronger emphasis on male fertility treatments, the widening use of injectable hormone therapies, and a sharper focus on controlled hormone delivery mechanisms.
Download A Free Sample Report For Comprehensive Market Insights:
Pregnyl Market Growth Drivers: What Factors Are Accelerating Expansion?
The expansion of healthcare infrastructure is set to boost the growth of the pregnyl market in the coming period. Healthcare infrastructure encompasses the physical and organizational frameworks, including facilities, resources, and systems, required to deliver healthcare services to a population. This expansion is fueled by factors such as an aging global population, rising chronic disease prevalence, and technological progress. A strong healthcare foundation fosters pregnyl’s growth by ensuring availability of fertility treatments, appropriate storage and administration facilities, and skilled medical personnel. For example, in January 2024, the American Hospital Association, a US-based professional organization, reported that the United States had 6,120 hospitals with 916,752 staffed beds and 33,679,935 total admissions across all facilities in 2024. Additionally, in May 2024, a report from the Office for National Statistics, a UK government agency, indicated that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Consequently, the expansion of healthcare infrastructure is propelling the pregnyl market forward.
Increasing infertility rates are anticipated to drive the growth of the Pregnyl market in the future. Infertility is defined as the inability to conceive after 12 months or more of regular unprotected sexual intercourse. This condition is becoming more common as many couples postpone childbearing until their late 30s, a time when fertility naturally declines. Pregnyl addresses infertility by facilitating assisted reproductive techniques, primarily through triggering ovulation or supporting the luteal phase. As an illustration, in April 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental agency of the United Nations, reported that approximately 17.5% of the adult population, or about 1 in 6 people globally, experiences infertility during their lifetime, challenging previous assumptions about regional variations. Hence, rising infertility rates are expected to fuel the expansion of the Pregnyl market.
Pregnyl Market Segment Landscape And Growth Potential
The pregnyl market covered in this report is segmented –
1) By Indication: Fertility Treatments In Women, Male Infertility, Hypogonadotropic Hypogonadism
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Fertility Clinics, Research Institutions, Other End-Users
Pregnyl Market Trends: What Is Shaping Future Industry Growth?
In July 2025, Organon & Co., a pharmaceutical enterprise headquartered in the United States, purchased Merck & Co., Inc.’s biotechnology production facility located at De Geer in Oss, with the financial terms of the transaction remaining undisclosed. This acquisition was intended by Organon to bolster its manufacturing capacities for fertility medications and to ensure a steady source of active pharmaceutical ingredients for its fertility product lineup, which encompasses human chorionic gonadotropin (hCG)-based treatments like Pregnyl. Notably, Merck & Co., Inc. is a Germany-based pharmaceutical organization that focuses on developing innovative drugs, vaccines, and healthcare solutions spanning key therapeutic fields.
Pregnyl Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the pregnyl market are Merck & Co.Inc.
Access The Complete Pregnyl Market Report:
Pregnyl Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the pregnyl market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pregnyl market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model